Rasonque Sales Top $198 Million in Five Weeks
Over 5,000 pancreatic cancer patients in the United States have already been treated with the newly approved drug.
Updated on Nov. 5, 2026 in Cancer
Revolution Medicines reported that its pancreatic cancer drug Rasonque, a pan-RAS inhibitor recently approved by the U.S. Food and Drug Administration, generated $198 million in sales in its first five weeks on the market. The company said more than 5,000 patients have been treated with the drug, and the figures are prompting investors to re-evaluate their forecasts for the product.
Why it matters
Pancreatic cancer is among the most difficult cancers to treat, so early uptake of a new targeted option is closely watched by patients and oncologists. The early sales and patient numbers offer a first signal of how quickly the drug is reaching people in the United States.
The figures come from the company's own disclosure on its third-quarter earnings call, not from an independent clinical study. They describe early commercial uptake, meaning how much the drug has been sold and how many patients have received it, rather than how well it works for patients.
The players
Revolution Medicines
A biopharmaceutical company focused on RAS-pathway cancer therapies, developer of the pancreatic cancer drug Rasonque.
U.S. Food and Drug Administration
The federal agency responsible for reviewing and approving prescription drugs and biologics for sale in the United States.
The details
Rasonque is a pan-RAS inhibitor, a type of targeted therapy designed to block RAS proteins, which are signaling molecules that drive tumor growth in many pancreatic cancers. Because the drug was approved by the FDA and launched in the United States only about five weeks before the company's earnings report, the sales and patient totals reflect a very early window of use. Revolution Medicines disclosed the figures on its earnings call on Wednesday evening, and Chief Commercial Officer Anthony Mancini described the U.S. launch as off to a strong start.
Timeline
Rasonque reached $198 million in sales five weeks after U.S. approval.
Revolution Medicines disclosed the sales and patient figures on its earnings call on November 4, 2026.
Health Landscape
Pancreatic cancer has historically had limited treatment options and poor survival outcomes, making new targeted approaches a major focus in oncology. RAS-directed drugs represent one of the more closely watched efforts to expand what clinicians can offer patients with this disease.
If you or someone you know has been diagnosed with pancreatic cancer, it is worth asking an oncologist whether newer targeted therapies such as RAS inhibitors may be appropriate for your specific tumor profile. Testing for the relevant genetic mutations is typically part of evaluating treatment options, so raising the question with your care team is a practical next step.
The takeaway
Early sales and patient numbers show that Rasonque is reaching a meaningful group of people quickly, but they do not yet show how well it works. Anyone considering newer targeted pancreatic cancer treatments should discuss genetic testing and eligibility with their oncologist.
Further reading
For more background on how new therapies reach patients, see our Cancer coverage.
